Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06792552 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumors, sponsored by NextCure.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 414
- Enrollment target
- 17
- Study locations
NCT06792552: Recruiting Phase 1 study of Advanced Solid Tumors, sponsored by NextCure.
NCT06792552 is a Phase 1 study of Advanced Solid Tumors that is actively recruiting participants, run by NextCure. The registered enrollment target is 414 participants, above the 196-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (111% higher). The trial reports 17 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06792552, a Phase 1 study of Advanced Solid Tumors, is actively recruiting participants, sponsored by NextCure.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 414 participants
- Enrollment target
- 17
- Study locations
Study Summary
This is an open-label, multicenter phase 1 study to evaluate the safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0505 in Adult Participants with Advanced Solid Tumors
Conditions Studied
Interventions
- DRUG SIM0505 for injection
Study Locations (17)
New York
- Roswell Park Cancer Institute - Buffalo
- Icahn School of Medicine at Mount Sinai - New York
China
- Liaoning Cancer Hospital & Institute - Shenyang
- The Fourth Hospital of Hebei Medical University (Heibei Tumor Hospital) - Shijiazhuang
Shandong
- Cancer Hospital of Shandong First Medical University - Jinan
- Affiliated Hospital of Jining Medical University - Jining
Florida
- Sarah Cannon Research Institute (SCRI) - Lake Nona - Orlando
Georgia
- Emory Winship Cancer Institute - Atlanta
Louisiana
- University Medical Center of New Orleans LSU-LCMC Health Cancer Center - New Orleans
Massachusetts
- Dana-Farber Cancer Institute - Boston
New Jersey
- Hackensack University Medical Center - Hackensack
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 414 participants |
| Start Date | 2025-02-26 |
| Est. Completion | 2028-08 |
| Phase | Phase 1 |
What NCT06792552 shows while recruiting
NCT06792552 is an interventional study that assigns participants to a tested intervention. The registered 414 participants enrollment target is mid-sized for trials with a published cap, above the 196-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (111% higher).
The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which SIM0505 for injection is the first listed.
NCT06792552 lists 17 locations in 14 states (New York, China, Shandong).
Frequently Asked Questions
What is clinical trial NCT06792552 about?
NCT06792552 is a clinical study titled "A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors". This is an open-label, multicenter phase 1 study to evaluate the safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0505 in Adult Participants with Advanced Solid Tumors
What is the current status of trial NCT06792552?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 414 participants. The study started on 2025-02-26. Estimated completion is 2028-08.
What conditions does trial NCT06792552 study?
This clinical trial studies the following conditions: Advanced Solid Tumors.
What interventions are being tested in trial NCT06792552?
The interventions under investigation include: SIM0505 for injection (DRUG).
Who is sponsoring clinical trial NCT06792552?
This trial is sponsored by NextCure, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06792552 being conducted?
This trial has 17 study locations across Florida, Georgia, Louisiana, Massachusetts, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06792552's enrollment target sits among peer trials
414 12th of 144 higher than 133 of 144 other Advanced Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
RECRUITING · Phase 1
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
RECRUITING · Phase 1
-
SNV4818 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04776941 · 414 participants · NA
Expressive Writing for the Management of Stress in Cancer Survivors
- NCT05142605 · 415 participants · NA
Evaluation of Grief Therapy Approaches for Bereaved Parents
- NCT03592472 · 413 participants · Phase 3
A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)
- NCT03527537 · 416 participants · Phase 4
Gestational Diabetes and Pharmacotherapy (GAP)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI